Milocor^®

Generic Name: Milrinone Lactate

Formulation: Vial containing 10 mL of concentrated injectable solution (1 mg/mL)

Drug Class: Inotropic agent

Indications: This drug is indicated for cardiac support in patients with acute heart failure.

Milocor^®

Milocor^® (Milrinone Lactate) is a selective inhibitor of the Phosphodiesterase-3 Enzyme in cardiac and vascular tissue, which affects the heart muscle's contraction strength. It is primarily used to enhance heart function in cases of heart failure.

Indications for Milocor^®

• Short-term treatment of decompensated heart failure.
• Cardiac support in patients experiencing shock or those post-heart transplant.

Dosage Form

Vial containing 10 mL of concentrated injectable solution (1 mg/mL).

Preparation of Milocor^®

To prepare Milocor^® for infusion, it is compatible with the following solutions:

• 0.45% Sodium Chloride
• 0.9% Sodium Chloride
• 5% Dextrose
• Ringer's Lactate

The diluted solution must be clear, colorless, and free of any particles or precipitates.

Dosing and Administration

• Milocor^® is for slow intravenous injection or intravenous infusion only. Do not administer outside the vein.
• This product is for single use only. Discard any remaining medication after use.

Monitoring During Milocor^® Use

• Blood pressure
• Heart rate
• ECG (electrocardiogram)
• Hemodynamic parameters (e.g., central venous pressure, mean arterial pressure, etc.)
• Intravenous volume status
• Renal function
• Urine output
• Electrolyte levels (especially potassium and magnesium)
• Platelet count

Contraindications for Milocor^®

• History of hypersensitivity to Milrinone or any of the formulation components.
• Severe depletion of intravascular fluid volume.

Warnings and Precautions for Milocor^®

• Patients with arrhythmias should be closely monitored during Milocor^® therapy, and the dosage should be carefully adjusted.
• Before and during treatment, correct any electrolyte imbalances, especially potassium or magnesium deficiencies.
• There is a risk of hypotension, particularly in patients with kidney dysfunction. If hypotension occurs, Milocor^® should be discontinued or the dose should be reduced.
• Milrinone should be used with caution in patients with renal insufficiency. The infusion rate may need to be reduced in these patients.

Use of Milocor^® During Pregnancy and Breastfeeding

• Consult your doctor before using Milrinone during pregnancy or breastfeeding.
• Milrinone use during pregnancy or breastfeeding should be done only after evaluating the risks and benefits, and under medical supervision.

Side Effects of Milocor^®

As with all medications, side effects may occur, though not all individuals will experience them. Some potential side effects include:

• Headache
• Hypotension (low blood pressure)
• Chest pain
• Reduced platelet count
• Hypokalemia (low potassium levels)

Drug Interactions

Consult your doctor or pharmacist before using Milocor® with other medications or supplements.

Packaging

Each package contains one vial.

Storage

• Store the medication at temperatures below 30°C, away from light, moisture, and freezing.
• Use the medication before the expiration date on the packaging.
• Keep the medication out of the reach of children.
• Do not remove the medication from its original packaging until ready to use.

References

1. Milrinone: Drug information, UpToDate 2025
2. Medicines.org.uk - Milrinone